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ments and adherence from June 2001 through December 2002.
Generalized Linear Models were estimated to examine the effects
of adherence on utilization patterns and expenditures in 2003.
RESULTS: Higher copayments led to lower levels of statin
adherence (Odds Ratio 0.75 p < 0.01 prevalent users, 0.72 p <
0.01 new users). For continuing users of statins higher levels of
statin adherence were associated with fewer adverse events: hos-
pitalizations (OR: 0.419 p = 0.01), cardiovascular hospitaliza-
tions (OR: 0.425 p = 0.046) and ER visits (OR: 0.219 p < 0.01).
Adherent patients had a larger number of physician ofﬁce visits
(OR: 14.84 p < 0.01 continuing users, 5.07 p < 0.01 new users)
and higher prescription drug expenditures (partial elasticity
0.204 p < 0.01 continuing users, 0.314 p < 0.01 new users).
However, medical expenditures and total (medical plus pre-
scription drug) expenditures for these patients were not signiﬁ-
cantly different from nonadherent patients. CONCLUSIONS:
Statin copayments serve as a ﬁnancial barrier to statin adherence.
Lower levels of adherence are associated with adverse cardio-
vascular and medical outcomes for patients remaining on statin
therapy. Policymakers and plan managers should consider effects
of higher statin copayments on adherence, utilization patterns
and clinical events.
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OBJECTIVES: Investigate how selection criteria and statistical
model speciﬁcations affect comparisons of alternative medica-
tions using retrospective database analyses. METHODS: Data
from the Medi-Cal Program were used to conduct a series of
head-to-head comparisons of alternative antipsychotics to test
the sensitivity of results to sample selection and model speciﬁ-
cation. OLS models were estimated for duration of therapy
deﬁned based on breaks in therapy >15 days. Five models were
compared: (1) a baseline model with only demographic inde-
pendent variables and selection criteria limited to age (18–100)
and prior eligibility >6 months; (2) screening for one year of
post-treatment data; (3) screening for schizophrenia; (4) addition
of prior diagnoses and utilization; and (5) addition of indepen-
dent variables for episode type. RESULTS: The baseline sample
consisted of 263,206 episodes. Average unadjusted days of
therapy for typical antipsychotics, olanzapine, risperidone and
quetiapine were 63, 138, 143 and 131, respectively. Model 1
found longer duration for all atypical antipsychotics relative to
conventional drugs (63–67 days). Risperidone exhibited longer
duration relative to olanzapine (+6 days, p < 0.0001) while olan-
zapine duration exceeded quetiapine by 8 days (p < 0.0001).
Duration for typicals increased from 63 days to 112 days in the
schizophrenia analysis (N = 70,650), reducing the estimated dif-
ferences favoring atypicals to 29–32 days (p < 0.0001). Adding
independent variables for prior utilization and diagnostic mix
reversed risperidone’s advantage over olanzapine from +6 to -4
days (p < 0.0001). Results favoring quetiapine over olanzapine
in duration of therapy on all antipsychotics was reversed from
+4 to +16 days to -3 days when covariates for episode type were
included in the model. CONCLUSIONS: Differences in duration
of antipsychotic therapy exist across diagnostic group and
episode type. Differences also exist in the diagnostic and episode
mix across drugs. Therefore, disaggregated patient samples and
expanded model speciﬁcations provide more accurate estimates
of differences in treatment duration.
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OBJECTIVES: To estimate the prevalence of diagnosis of atten-
tion-deﬁcit/hyperactivity disorder (ADHD) and use of stimulants
for children aged 3–18 years in the US ambulatory settings.
METHODS: Data from the National Ambulatory Medical Care
Survey (NAMCS) and the National Hospital Ambulatory
Medical Care Survey (NHAMCS) 1993–2003 were used. The
main outcome measures were annual visits with diagnosis of
ADHD, visits with prescription of stimulants, and proportion of
stimulants prescribed in visits with diagnosis of ADHD. Diag-
nosis of ADHD was determined using ICD-9-CM code 314.
Stimulants (methylphenidate, dexmethylphenidate, pemoline,
and amphetamine compounds) were identiﬁed by generic codes.
95% conﬁdence intervals were calculated and PROC SUR-
VEYFREQ in SAS 9.1 was used to account for the complex sam-
pling designs of these surveys. The results were weighted to
reﬂect national estimates. RESULTS: Outpatient visits made by
children 3–18 years of age increased from 131 (95% CI:
109–153) million in 1993 to 165 (137–192) million in 2003.
Diagnosis of ADHD increased 127%, from 3.2 (1.3–5.2) million
to 7.4 (5.2–9.5) million, accounted for 2.5% (1.0%–3.9%) and
4.5% (3.4%–5.6%) of all visits made by children in 1993 and
2003, respectively. Visits with stimulants prescribed jumped
from 2.7 (0.9–4.5) million in 1993 to 6.6 (4.5–8.7) million in
2003. Proportion of stimulant use in children doubled over this
period, from 2.1% (0.7%–3.4%) to 4.0% (3.0%–5.0%). Pro-
portion of children with ADHD treated with stimulants ranged
from 64.0% in 1997 to 77.3% in 1996, with an average of
70.4% (68.1%–72.8%) over the years studied. CONCLU-
SIONS: There was a steady growth in prevalence of ADHD and
stimulant use among children aged 3–18 years in the US between
1993 and 2003. Approximately 70% children with ADHD were
treated with stimulants. As appropriateness of treatment could
not be determined in the current databases, whether this per-
centage represents overutilization of underutilization of stimu-
lants merits further studies.
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OBJECTIVE: To assess the clinical characteristics and medica-
tion patterns of patients with schizophrenia treated with typical
depot antipsychotics compared with oral antipsychotics in the
usual care setting in Australia. METHODS: This was a prospec-
tive, single-site, observational study of 348 subjects with schiz-
ophrenia assessed at six-month intervals over three years. Data
were collected via face-to-face interviews by research personnel
and from external information systems to evaluate resource util-
isation. The two groups were compared for demographic and
clinical characteristics at baseline, co-therapy use, rate and
average length of stay (ALoS) of hospitalisation over the three
years. Analysis of variance was used to compare continuous vari-
ables, whereas the chi-square test was used for categorical out-
comes. RESULTS: A total of 144 and 179 patients were treated
